Immunostimulation in chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a one-year prospective, double-blind, placebo-controlled study

World Journal of Urology

Volumn 32, Issue 6, 2014, Pages 1595-1603

  Wagenlehner, Florian M E ^a   Ballarini, Stefania ^b   Naber, Kurt G ^c  

^a JUSTUS LIEBIG UNIVERSITY   (Germany)

^b Vifor (International) Inc   (Switzerland)

^c TECHNICAL UNIVERSITY OF MUNICH   (Germany)

Author keywords

Chronic prostatitis chronic pelvic pain syndrome; Immunostimulation; Placebo effect

Indexed keywords

BACTERIAL ANTIGEN; IMMUNOLOGICAL ADJUVANT; OM 89;

ADULT; CHRONIC PAIN; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG ADMINISTRATION; HUMAN; MALE; MIDDLE AGED; MULTICENTER STUDY; PELVIC PAIN; PHASE 3 CLINICAL TRIAL; PILOT STUDY; PROSTATITIS; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

ADJUVANTS, IMMUNOLOGIC; ADULT; ANTIGENS, BACTERIAL; CHRONIC PAIN; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; HUMANS; MALE; MIDDLE AGED; PELVIC PAIN; PILOT PROJECTS; PROSTATITIS; TREATMENT OUTCOME;

EID: 84911993456     PISSN: 07244983     EISSN: 14338726     Source Type: Journal    
DOI: 10.1007/s00345-014-1247-z     Document Type: Article

References (28)

1. Weidner W, Schiefer HG, Krauss H, Jantos C, Friedrich HJ, Altmannsberger M (1991) Chronic prostatitis: a thorough search for etiologically involved microorganisms in 1,461 patients. Infection 19(Suppl 3):S119–S125
2. Krieger JN, Riley DE, Cheah PY, Liong ML, Yuen KH (2003) Epidemiology of prostatitis: new evidence for a world-wide problem. World J Urol 21:70–74
3. Pontari MA (2013) Etiology of chronic prostatitis/chronic pelvic pain syndrome: psychoimmunoneurendocrine dysfunction (PINE syndrome) or just a really bad infection? World J Urol
4. Hochreiter WW, Nadler RB, Koch AE, Campbell PL, Ludwig M, Weidner W, Schaeffer AJ (2000) Evaluation of the cytokines interleukin 8 and epithelial neutrophil activating peptide 78 as indicators of inflammation in prostatic secretions. Urology 56:1025–1029
5. Alexander RB, Brady F, Ponniah S (1997) Autoimmune prostatitis: evidence of T cell reactivity with normal prostatic proteins. Urology 50:893–899
6. Anothaisintawee T, Attia J, Nickel JC, Thammakraisorn S, Numthavaj P, McEvoy M, Thakkinstian A (2011) Management of chronic prostatitis/chronic pelvic pain syndrome: a systematic review and network meta-analysis. JAMA 305:78–86
7. Cohen JM, Fagin AP, Hariton E, Niska JR, Pierce MW, Kuriyama A, Whelan JS, Jackson JL, Dimitrakoff JD (2012) Therapeutic intervention for chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): a systematic review and meta-analysis. PLoS ONE 7:e41941
8. Magri V, Wagenlehner F, Perletti G, Schneider S, Marras E, Naber KG, Weidner W (2010) Use of the UPOINT chronic prostatitis/chronic pelvic pain syndrome classification in European patient cohorts: sexual function domain improves correlations. J Urol 184:2339–2345
9. Shoskes DA, Nickel JC, Dolinga R, Prots D (2009) Clinical phenotyping of patients with chronic prostatitis/chronic pelvic pain syndrome and correlation with symptom severity. Urology 73:538–542 (discussion 542-533)
10. Shoskes DA, Nickel JC, Kattan MW (2010) Phenotypically directed multimodal therapy for chronic prostatitis/chronic pelvic pain syndrome: a prospective study using UPOINT. Urology 75:1249–1253
11. Fitzgerald MP, Anderson RU, Potts J, Payne CK, Peters KM, Clemens JQ, Kotarinos R, Fraser L, Cosby A, Fortman C, Neville C, Badillo S, Odabachian L, Sanfield A, O’Dougherty B, Halle-Podell R, Cen L, Chuai S, Landis JR, Mickelberg K, Barrell T, Kusek JW, Nyberg LM (2013) Randomized multicenter feasibility trial of myofascial physical therapy for the treatment of urological chronic pelvic pain syndromes. J Urol 189:S75–S85
12. Nickel JC, O’Leary MP, Lepor H, Caramelli KE, Thomas H, Hill LA, Hoel GE (2011) Silodosin for men with chronic prostatitis/chronic pelvic pain syndrome: results of a phase II multicenter, double-blind, placebo controlled study. J Urol 186:125–131
13. Bosch A, Benedi VJ, Pares R, Jofre J (1988) Enhancement of the humoral immune response and resistance to bacterial infection in mice by the oral administration of a bacterial immunomodulator (OM-89). Immunopharmacol Immunotoxicol 10:333–343
14. Van Pham T, Kreis B, Corradin-Betz S, Bauer J, Mauel J (1990) Metabolic and functional stimulation of lymphocytes and macrophages by an Escherichia coli extract (OM-89): in vitro studies. J Biol Response Mod 9:231–240
15. Schmidhammer S, Ramoner R, Holtl L, Bartsch G, Thurnher M, Zelle-Rieser C (2002) An Escherichia coli-based oral vaccine against urinary tract infections potently activates human dendritic cells. Urology 60:521–526
16. Lee SJ, Kim SW, Cho YH, Yoon MS (2006) Anti-inflammatory effect of an Escherichia coli extract in a mouse model of lipopolysaccharide-induced cystitis. World J Urol 24:33–38
17. Brackertz D, Vischer TL (1989) OM-8980 in rheumatoid arthritis: a 6-month double blind placebo controlled multicenter study. J Rheumatol 16:19–23
18. Chiavaroli C, Moore A (2006) An hypothesis to link the opposing immunological effects induced by the bacterial lysate OM-89 in urinary tract infection and rheumatoid arthritis. BioDrugs 20:141–149
19. Wagenlehner FM, Bschleipfer T, Pilatz A, Weidner W (2011) Pollen extract for chronic prostatitis-chronic pelvic pain syndrome. Urol Clin North Am 38:285–292
20. Wagenlehner FM, Schneider H, Ludwig M, Schnitker J, Brahler E, Weidner W (2009) A pollen extract (Cernilton) in patients with inflammatory chronic prostatitis-chronic pelvic pain syndrome: a multicentre, randomised, prospective, double-blind, placebo-controlled phase 3 study. Eur Urol 56:544–551
21. Bauer HW, Alloussi S, Egger G, Blumlein HM, Cozma G, Schulman CC (2005) A long-term, multicenter, double-blind study of an Escherichia coli extract (OM-89) in female patients with recurrent urinary tract infections. Eur Urol 47:542–548 (discussion 548)
22. Naber KG, Cho YH, Matsumoto T, Schaeffer AJ (2009) Immunoactive prophylaxis of recurrent urinary tract infections: a meta-analysis. Int J Antimicrob Agents 33:111–119
23. Nickel JC, Nyberg LM, Hennenfent M (1999) Research guidelines for chronic prostatitis: consensus report from the first National Institutes of Health International Prostatitis Collaborative Network. Urology 54:229–233
24. Krieger JN, Nyberg L Jr, Nickel JC (1999) NIH consensus definition and classification of prostatitis. JAMA 282:236–237
25. Litwin MS, McNaughton-Collins M, Fowler FJ Jr, Nickel JC, Calhoun EA, Pontari MA, Alexander RB, Farrar JT, O’Leary MP (1999) The National Institutes of Health chronic prostatitis symptom index: development and validation of a new outcome measure. chronic prostatitis collaborative research network. J Urol 162:369–375
26. Wagenlehner FM, van Till JW, Magri V, Perletti G, Houbiers JG, Weidner W, Nickel JC (2013) National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) symptom evaluation in multinational cohorts of patients with chronic prostatitis/chronic pelvic pain syndrome. Eur Urol 63:953–959
27. Nickel JC, Shoskes DA, Wagenlehner FM (2013) Management of chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS): the studies, the evidence, and the impact. World J Urol 31:747–753
28. Shoskes DA, Nickel JC (2013) Classification and treatment of men with chronic prostatitis/chronic pelvic pain syndrome using the UPOINT system. World J Urol 31:755–760